Sensory Organ Drugs - Switzerland

In Switzerland, the revenue for the Sensory Organ Drugs market is forecasted to reach US$156.00m in 2024.
It is anticipated that the revenue will exhibit a compound annual growth rate (CAGR 2024-2029) of -3.49%, leading to a market volume of US$130.60m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$13.98bn in 2024.
Switzerland, known for its strong pharmaceutical industry, is at the forefront of developing innovative sensory organ drugs.

Definition:
This market covers ophthalmologicals and otologicals, i.e., drugs for the sensory organs eye and ear, respectively. Ophthalmologicals are used to treat diseases of the eye such as wet age-related macular degeneration, geographic atrophy, and glaucoma. Typical dosage forms are eye drops or injections into the eye (intravitreal) and, in the case of otologicals, through the eardrum into the middle ear.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Regeneron Pharmaceuticals, Novartis, Bayer, Alcon, AbbVie

Ophthalmologicals
Otologicals

Respiratory system
Ophthalmic devices, such as diagnostic and surgical devices or glasses and contact lenses
Dermatology, skin treatment
Painkillers, analgesics

The Sensory Organ Drugs market in Switzerland has been experiencing steady growth in recent years.

Customer preferences: Swiss customers have been showing an increasing demand for sensory organ drugs due to the aging population and a rise in chronic eye diseases. Additionally, there has been a growing trend towards preventive healthcare, which has led to an increase in the number of people seeking treatment for early-stage eye diseases.

Trends in the market: One of the major trends in the Sensory Organ Drugs market in Switzerland is the increasing adoption of combination therapies. Combination therapies are becoming more popular due to their higher efficacy and lower side effects, compared to single-drug therapies. Additionally, there has been a growing trend towards the development of gene therapies for the treatment of inherited eye diseases.

Local special circumstances: Switzerland is home to several leading pharmaceutical companies, which has led to a highly competitive market for Sensory Organ Drugs. The country also has a well-established healthcare system, which has been instrumental in driving the growth of the market. Additionally, there has been a growing trend towards the use of digital technologies in the treatment of eye diseases, which has led to the development of several innovative products in the market.

Underlying macroeconomic factors: The Swiss economy has been performing well in recent years, with a stable political environment and a highly skilled workforce. Additionally, the country has a high level of healthcare expenditure, which has been instrumental in driving the growth of the Sensory Organ Drugs market. The aging population and the rise in chronic eye diseases have also been key drivers of the market growth.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.